Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2013 Aug 26;8(8):e70044.
doi: 10.1371/journal.pone.0070044. eCollection 2013.

Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis

Irit Ben-Aharon  1 , Liat Vidal, Shulamith Rizel, Rinat Yerushalmi, Ofer Shpilberg, Aaron Sulkes, Salomon M Stemmer
Affiliations
Meta-Analysis

Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis

Irit Ben-Aharon et al. PLoS One. .

Abstract

Background: The role of bisphosphonates (BP) in early breast cancer (BC) has been considered controversial. We performed a meta-analysis of all randomized controlled trials (RCTs) that appraised the effects of BP on survival in early BC.

Methods: RCTs were identified by searching the Cochrane Library, MEDLINE databases and conference proceedings. Hazard ratios (HRs) of overall survival (OS), disease-free survival (DFS) and relative risks of adverse events were estimated and pooled.

Results: Thirteen trials met the inclusion criteria, evaluating a total of 15,762 patients. Meta-analysis of ten trials which reported OS revealed no statistically significant benefit in OS for BP (HR 0.89, 95% CI = 0.79 to 1.01). Meta-analysis of nine trials which reported the DFS revealed no benefit in DFS (HR 0.95 (0.81-1.12)). Meta-analysis upon menopausal status showed a statistically significant better DFS in the BP-treated patients (HR 0.81(0.69-0.95)). In meta-regression, chemotherapy was negatively associated with HR of survival.

Conclusions: Our meta-analysis indicates a positive effect for adjuvant BP on survival only in postmenopausal patients. Meta-regression demonstrated a negative association between chemotherapy use BP effect on survival. Further large scale RCTs are warranted to unravel the specific subgroups that would benefit from the addition of BP in the adjuvant setting.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: Salomon M. Stemmer is an editor of PLOS ONE. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

Figures

Figure 1
Figure 1. Randomized controlled trials search and selection.
Figure 2
Figure 2. Forest plot of hazard ratios (HRs) comparing (A) overall survival or (B) disease-free survial (DFS) for patients who received BP in addition to standard therapy vs. those who received standard therapy only.
Hazard ratios for each trail are represented by the squares, the size of the square represents the weight of the trial in the meta-analysis, and the horizontal line crossing the square represents the 95% confidence interval (CI). The diamonds represent the estimated overall effect based on the meta-analysis random effect of all trials.
Figure 3
Figure 3. Forest plot of hazard ratios comparing disease-free survival for most-menopausal patients who received BP in addition to standard therapy vs. those who received standard therapy only.
Hazard ratios for each trail are represented by the squares, the size of the square represents the weight of the trial in the meta-analysis, and the horizontal line crossing the square represents the 95% confidence interval (CI). The diamonds represent the estimated overall effect based on the meta-analysis random effect of all trials.
Figure 4
Figure 4. Meta regression of hazard ratios of overall survival in individual studies assessing the effect of percentage of patients receiving chemotherapy in addition to endocrine therapy.
See this image and copyright information in PMC

References

    1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893–2917. - PubMed
    1. Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12: 6243s–6249s. - PubMed
    1. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, et al. (2000) Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60: 2949–2954. - PubMed
    1. Van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Löwik C, et al. (1996) Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 98: 698–705. - PMC - PubMed
    1. Gallo M, De Luca A, Lamura L, Normanno N (2011) Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer. Ann Oncol 1: 1–7. - PubMed

MeSH terms